Active Ingredient History
Granisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT3 receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting. Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone. Granisetron is used for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bariatric Surgery (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Cholelithiasis (Phase 4)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 2)
Gastroparesis (Phase 3)
General Surgery (Phase 3)
Glioma (Phase 2)
Granisetron (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Heart (Phase 4)
HIV Infections (Phase 2)
Hypotension (Phase 4)
Leukemia (Phase 4)
Lymphoma (Phase 4)
Myofascial Pain Syndromes (Phase 4)
Nausea ()
Neoplasms (Phase 4)
Pharmacokinetics (Phase 3)
Postoperative Complications (Phase 3)
Prostatic Neoplasms (Phase 4)
Pruritus (Phase 2)
Respiratory Aspiration (Early Phase 1)
Sepsis (Phase 2)
Temporomandibular Joint Disorders (Phase 4)
Testicular Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 3)
Vomiting (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
